On December 7, 2022, Casdin Capital, LLC announced that it has been and might continue to be in contact with members of Tenaya Therapeutics, Inc.'s management, the Company's Board of Directors, other significant shareholders and others regarding alternatives that the Company could employ to maximize shareholder value.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.31 USD | +2.13% | -0.23% | +33.02% |
Mar. 20 | Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating | MT |
Mar. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.02% | 331M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- TNYA Stock
- News Tenaya Therapeutics, Inc.
- Casdin Capital Engages in Discussions with Tenaya Therapeutics